ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of “Moderate Buy” from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $77.00.

Several equities analysts have commented on the company. Raymond James increased their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. Truist Financial reiterated a “hold” rating and issued a $60.00 target price (down from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. HC Wainwright restated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Finally, StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th.

ANI Pharmaceuticals Trading Up 0.8 %

Shares of NASDAQ:ANIP opened at $60.12 on Friday. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $1.26 billion, a PE ratio of 37.58 and a beta of 0.71. ANI Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $70.81. The firm has a fifty day moving average price of $59.37 and a 200 day moving average price of $62.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. The company had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business’s quarterly revenue was up 18.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.06 earnings per share. Analysts expect that ANI Pharmaceuticals will post 3.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC lifted its stake in shares of ANI Pharmaceuticals by 287.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock valued at $1,471,000 after buying an additional 15,790 shares during the period. BNP Paribas Financial Markets lifted its position in shares of ANI Pharmaceuticals by 106.9% in the 1st quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock worth $1,434,000 after acquiring an additional 10,716 shares during the period. Wakefield Asset Management LLLP acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $979,000. Sequoia Financial Advisors LLC bought a new stake in shares of ANI Pharmaceuticals during the second quarter valued at approximately $600,000. Finally, Lisanti Capital Growth LLC bought a new stake in shares of ANI Pharmaceuticals during the first quarter valued at approximately $2,218,000. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.